287 related articles for article (PubMed ID: 17203231)
1. Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens.
Leblanc K; Sexton E; Parent S; Bélanger G; Déry MC; Boucher V; Asselin E
Int J Oncol; 2007 Feb; 30(2):477-87. PubMed ID: 17203231
[TBL] [Abstract][Full Text] [Related]
2. Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta.
Kumar A; Klinge CM; Goldstein RE
Int J Oncol; 2010 May; 36(5):1067-80. PubMed ID: 20372779
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of estrogen and antiestrogen on transforming growth factor gene expression in endometrial adenocarcinoma cells.
Gong Y; Ballejo G; Murphy LC; Murphy LJ
Cancer Res; 1992 Apr; 52(7):1704-9. PubMed ID: 1551100
[TBL] [Abstract][Full Text] [Related]
4. Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation.
Hoffman KL; Lerner SP; Smith CL
Horm Cancer; 2013 Feb; 4(1):24-35. PubMed ID: 22965848
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.
Obrero M; Yu DV; Shapiro DJ
J Biol Chem; 2002 Nov; 277(47):45695-703. PubMed ID: 12244117
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release.
Kansra S; Yamagata S; Sneade L; Foster L; Ben-Jonathan N
Mol Cell Endocrinol; 2005 Jul; 239(1-2):27-36. PubMed ID: 15950373
[TBL] [Abstract][Full Text] [Related]
7. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.
Vivacqua A; Bonofiglio D; Recchia AG; Musti AM; Picard D; Andò S; Maggiolini M
Mol Endocrinol; 2006 Mar; 20(3):631-46. PubMed ID: 16239258
[TBL] [Abstract][Full Text] [Related]
8. Differential SERM effects on corepressor binding dictate ERalpha activity in vivo.
Webb P; Nguyen P; Kushner PJ
J Biol Chem; 2003 Feb; 278(9):6912-20. PubMed ID: 12482846
[TBL] [Abstract][Full Text] [Related]
9. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites.
Paech K; Webb P; Kuiper GG; Nilsson S; Gustafsson J; Kushner PJ; Scanlan TS
Science; 1997 Sep; 277(5331):1508-10. PubMed ID: 9278514
[TBL] [Abstract][Full Text] [Related]
10. Hemodynamic effects of acute and repeated exposure to raloxifene in ovariectomized sheep.
Zoma WD; Baker RS; Mershon JL; Clark KE
Am J Physiol Heart Circ Physiol; 2006 Sep; 291(3):H1216-25. PubMed ID: 16517945
[TBL] [Abstract][Full Text] [Related]
11. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.
Shen SS; Smith CL; Hsieh JT; Yu J; Kim IY; Jian W; Sonpavde G; Ayala GE; Younes M; Lerner SP
Cancer; 2006 Jun; 106(12):2610-6. PubMed ID: 16700038
[TBL] [Abstract][Full Text] [Related]
12. Changes in oestrogen receptor-alpha and -beta during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells.
Shaw LE; Sadler AJ; Pugazhendhi D; Darbre PD
J Steroid Biochem Mol Biol; 2006 Apr; 99(1):19-32. PubMed ID: 16533599
[TBL] [Abstract][Full Text] [Related]
13. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta.
Tee MK; Rogatsky I; Tzagarakis-Foster C; Cvoro A; An J; Christy RJ; Yamamoto KR; Leitman DC
Mol Biol Cell; 2004 Mar; 15(3):1262-72. PubMed ID: 14699072
[TBL] [Abstract][Full Text] [Related]
14. Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.
Bianco NR; Perry G; Smith MA; Templeton DJ; Montano MM
Mol Endocrinol; 2003 Jul; 17(7):1344-55. PubMed ID: 12714703
[TBL] [Abstract][Full Text] [Related]
15. Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis.
Chen Y; Li Z; He Y; Shang D; Pan J; Wang H; Chen H; Zhu Z; Wan L; Wang X
Toxicol Appl Pharmacol; 2014 Mar; 275(2):176-81. PubMed ID: 24440569
[TBL] [Abstract][Full Text] [Related]
16. Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus.
Stygar D; Muravitskaya N; Eriksson B; Eriksson H; Sahlin L
Reprod Biol Endocrinol; 2003 May; 1():40. PubMed ID: 12777179
[TBL] [Abstract][Full Text] [Related]
17. Estrogen modulates in vitro T cell responses in a concentration- and receptor-dependent manner: effects on intracellular molecular targets and antioxidant enzymes.
Priyanka HP; Krishnan HC; Singh RV; Hima L; Thyagarajan S
Mol Immunol; 2013 Dec; 56(4):328-39. PubMed ID: 23911387
[TBL] [Abstract][Full Text] [Related]
18. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells.
Kim K; Thu N; Saville B; Safe S
Mol Endocrinol; 2003 May; 17(5):804-17. PubMed ID: 12576490
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide transcriptional regulation of estrogen receptor targets in fallopian tube cells and the role of selective estrogen receptor modulators.
Moyle-Heyrman G; Schipma MJ; Dean M; Davis DA; Burdette JE
J Ovarian Res; 2016 Feb; 9():5. PubMed ID: 26879975
[TBL] [Abstract][Full Text] [Related]
20. Identification of coregulators influenced by estrogen receptor subtype specific binding of the ER antagonists 4-hydroxytamoxifen and fulvestrant.
Evers NM; Wang S; van den Berg JH; Houtman R; Melchers D; de Haan LH; Ederveen AG; Groten JP; Rietjens IM
Chem Biol Interact; 2014 Sep; 220():222-30. PubMed ID: 25014417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
